Income statement, balance sheet and cash flow statement for the last 6 fiscal years, taken from the XBRL data Renalytix plc files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
Revenue
0
1.49
2.97
3.4
2.29
Cost of revenue
0
0.86
2.1
2.68
2.13
Gross profit
0
0.63
0.87
0.72
0.16
Research and development
4.32
4.57
10
14.6
14.3
9.29
General and administrative
2.74
5.75
23.5
39.5
28.7
19.8
Operating expenses
42.3
10.3
32.5
54.1
42.9
29.8
Operating income
-42.3
-10.3
-31.9
-53.2
-42.2
-29.6
Other non-operating income
0.02
0.29
0.73
0.66
0.25
Pre-tax income
-42.3
-9.84
-35.3
-45.3
-45.6
-33.5
Income tax
0
0
0.03
0
0
Net income to minority interests
0
0.61
0
Net income
-42.3
-9.84
-35.3
-45.3
-45.6
-33.5
EBITDA
-42.3
-10.2
-31.6
-52.7
-41.7
-29.2
EPS, basic
-0.99
-0.17
-0.49
-0.62
-0.55
-0.31
EPS, diluted
-0.99
-0.17
-0.49
-0.67
-0.55
-0.31
Shares, basic (weighted)
42.6
59.1
71.5
72.9
82.2
108
Shares, diluted (weighted)
42.6
59.1
71.5
73.8
82.2
108
Balance sheet
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
Cash and equivalents
8.2
13.3
65.1
41.3
24.7
4.68
Short-term investments
0.99
0.98
0
Receivables
0.59
0.9
0.78
0.72
Other current assets
0.23
0.55
0.99
2.45
1.42
0.72
Total current assets
9.42
14.8
66.8
44.8
26.9
6.12
Property, plant and equipment
0.28
1.66
2.49
1.37
1.03
0.22
Lease right-of-use assets
0
0.16
0
Intangible assets
1.23
1.19
1.05
0.87
Total assets
9.7
20.9
78.6
50.1
30.6
7.97
Accounts payable
0.32
2.22
1.4
1.38
Accrued liabilities
0.83
0.68
4.6
3.06
6.64
3.35
Deferred revenue
0.12
0.05
0
Total current liabilities
1.15
3.29
7.06
11.8
16.1
11.5
Lease liabilities
0
0.04
0
Other non-current liabilities
0.05
Total liabilities
1.15
4.97
7.12
19.5
23.7
15.8
Paid-in capital
52.1
69.7
150
164
186
205
Retained earnings
-42.9
-52.7
-87.4
-133
-178
-212
Other comprehensive income
-0.82
-1.2
8.28
-0.92
-1.45
-1.44
Shareholders' equity
8.55
15.9
71.5
30.6
6.97
-7.85
Total equity
8.55
15.9
71.5
30.6
6.97
-7.85
Total liabilities and equity
9.7
20.9
78.6
50.1
30.6
7.97
Shares outstanding
53.8
59.4
72.2
74.8
93.8
154
Cash flow statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
Net income
-42.3
-9.84
-35.3
-45.3
-45.6
-33.5
Depreciation and amortization
0.03
0.07
0.28
0.49
0.51
0.36
Stock-based compensation
0.53
1.16
2.66
4.62
2.93
1.71
Change in receivables
-0.59
-0.31
0.13
0.05
Change in payables
0.3
0.36
0.78
1.42
Cash from operations
-6.16
-9.52
-28.4
-45.9
-34.1
-30.1
Capital expenditures
-0.31
-0.8
-0.77
-0.56
0
Purchases of investments
-4.97
-21.3
Cash from investing
-12.3
-1.17
-0.75
-0.66
0
-0
Stock issued
29.1
17.3
0.25
8.8
20.3
13.5
Cash from financing
27.4
15.9
77.2
25.6
16.4
10.3
Exchange rate effect
-0.81
-0.15
3.75
-2.84
1.05
-0.14
Net change in cash
8.12
5.09
51.8
-23.8
-16.7
-20
Free cash flow
-6.47
-10.3
-29.2
-46.5
-34.1
Interest paid
0.02
0
0.25
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to September 30, 2024; growth uses fiscal years. Valuation uses the share price of $0.09 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
12.7%
Gross profit / revenue.
Operating margin
-1,055.0%
Operating income / revenue.
EBITDA margin
-1,045.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-1,191.0%
Pre-tax income / revenue.
Net margin
-1,192.0%
Net income / revenue.
Operating cash flow margin
-1,039.0%
Cash from operations / revenue.
Return on assets (ROA)
-584.7%
Net income / average total assets.
R&D / revenue
315.6%
Research and development expense / revenue.
Stock-based pay / revenue
61.4%
Stock-based compensation (from the cash flow statement) / revenue.
D&A / revenue
10.2%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-32.7%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
15.4%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit growth, 1y
-78.3%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
-37.3%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value growth, 1y
-212.7%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-74.0%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-53.4%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-3.8%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
31.6%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
14.8%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
20.5%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.24x
Current assets / current liabilities.
Quick ratio
0.15x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.08x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.02
Revenue / diluted weighted shares.
Operating cash flow per share
-$0.23
Cash from operations / diluted weighted shares.
Book value per share
-$0.07
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
12.4x
Market cap / revenue.
EV/Sales
12.0x
Enterprise value / revenue.
Earnings yield
-96.2%
Net income / market cap (the inverse of P/E).
What was Renalytix plc's revenue in fiscal 2024?
Renalytix plc reported revenue of $2.3M for fiscal 2024, 32.7% lower than the year before.
Was Renalytix plc profitable in fiscal 2024?
No. It reported a net loss of $33.5M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.